Inhibition of inducible nitric oxide synthase by beta-lapachone in rat alveolar macrophages and aorta

Br J Pharmacol. 1999 Feb;126(3):746-50. doi: 10.1038/sj.bjp.0702341.

Abstract

Beta-lapachone, a plant product, has been shown to be a novel inhibitor of DNA topoisomerase. In this study, we performed experiments to examine the effects of beta-lapachone on lipopolysaccharide (LPS)-induced inducible nitric oxide (NO) synthase (iNOS) in rat alveolar macrophages and aortic rings. In alveolar macrophages, incubation with LPS (10 microg ml(-1)) for various time intervals resulted in a significant increase in nitrite production and iNOS protein synthesis, that was inhibited by coincubation with beta-lapachone (1-4.5 microM) without any cytotoxic effects. However, addition of beta-lapachone after induction of NO synthase by LPS failed to affect the nitrite production. Treatment with LPS (10 microg ml(-1)) for 6 h resulted in significant expression of mRNA for iNOS which was significantly inhibited in the presence of beta-lapachone (3 microM) in alveolar macrophages. In endothelium-intact rings of thoracic aorta, beta-lapachone (1 and 3 microM) markedly inhibited the hypocontractility to phenylephrine in aortic rings treated with LPS (10 microg ml(-1)) for 4 h. When beta-lapachone was added 3 h after LPS into the medium, the contractions evoked by phenylephrine were not significantly different in the presence or absence of beta-lapachone. Treatment with LPS (10 microg ml(-1)) for 4 h resulted in a significant increase in iNOS protein synthesis which was inhibited in the presence of beta-lapachone (3 microM), but did not affect the constitutive (endothelial and neuronal) NOS forms in aortic rings. These results indicate that beta-lapachone is capable of inhibiting expression and function of iNOS in rat alveolar macrophages and aortic rings. It is considered that beta-lapachone can be developed as a potential anti-inflammatory agent in the future.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Aorta, Thoracic / drug effects*
  • Aorta, Thoracic / enzymology
  • Aorta, Thoracic / physiology
  • Cell Line
  • Dose-Response Relationship, Drug
  • Endothelium, Vascular / physiology
  • Enzyme Inhibitors / pharmacology*
  • Humans
  • In Vitro Techniques
  • Lipopolysaccharides / pharmacology
  • Macrophages, Alveolar / drug effects*
  • Macrophages, Alveolar / enzymology
  • Male
  • Muscle Contraction / drug effects
  • Naphthoquinones / pharmacology*
  • Nitric Oxide Synthase / antagonists & inhibitors*
  • Nitric Oxide Synthase / drug effects
  • Nitric Oxide Synthase / metabolism
  • Nitric Oxide Synthase Type I
  • Nitric Oxide Synthase Type II
  • Nitric Oxide Synthase Type III
  • Nitrites / metabolism
  • Phenylephrine / pharmacology
  • Rats
  • Rats, Wistar
  • Topoisomerase I Inhibitors
  • Vasoconstrictor Agents / pharmacology

Substances

  • Enzyme Inhibitors
  • Lipopolysaccharides
  • Naphthoquinones
  • Nitrites
  • Topoisomerase I Inhibitors
  • Vasoconstrictor Agents
  • Phenylephrine
  • beta-lapachone
  • NOS1 protein, human
  • NOS2 protein, human
  • NOS3 protein, human
  • Nitric Oxide Synthase
  • Nitric Oxide Synthase Type I
  • Nitric Oxide Synthase Type II
  • Nitric Oxide Synthase Type III
  • Nos1 protein, rat
  • Nos2 protein, rat
  • Nos3 protein, rat